Literature DB >> 10928580

Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.

H T Benamer1, J Patterson, D J Wyper, D M Hadley, G J Macphee, D G Grosset.   

Abstract

The variability in clinical features and the masking effects of drug therapy in Parkinson's disease (PD) can affect clinical assessment of disease severity. The aim of this study was to assess the imaging of dopamine transporters using 123I-FP-CIT SPECT and its correlation with disease staging, severity, and duration. Differences between the clinical severity of the onset and non-onset side and the corresponding striatal uptake ratios were also examined. Forty-one patients with PD (nine unilateral, 32 bilateral clinical features) were studied. Clinical severity was determined by using the Unified Parkinson's Disease Rating Score (UPDRS). Unilateral UPDRS was calculated from unilateral arm and leg resting and action tremor, rigidity, finger taps, hand movements, alternating movements, and leg agility. 123I-FP-CIT striatal uptake was expressed as the ratio of specific:nonspecific (SP:NS) uptake for defined brain areas. Patients with PD who had unilateral symptoms showed a significant difference between the ipsilateral and contralateral SP:NS ratios in both the caudate and putamen, but there was a considerable overlap between between the two sides. This result was repeated in patients with bilateral symptoms and there was overlap of SP:NS ratios between the two groups. For the whole group of patients with PD, striatum, caudate, and putamen SP:NS ratios correlated with disease severity assessed by UPDRS and duration of disease. The SP:NS ratios correlated with the bradykinesia subscore but not with rigidity or tremor subscore. In conclusion, this study provides further evidence that the SP:NS ratio is a robust measure of disease severity correlating with duration of PD. However, variability in uptake values suggest that factors other than nigrostriatal degeneration may contribute to disease severity. Correlation with bradykinesia but not with tremor may indicate an origin for tremor outwith the dopamine transporter system. 123I-FP-CIT SPECT offers significant potential in defining the nigrostriatal changes in PD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928580     DOI: 10.1002/1531-8257(200007)15:4<692::aid-mds1014>3.0.co;2-v

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  98 in total

1.  Cerebral cortical areas in which thickness correlates with severity of motor deficits of Parkinson's disease.

Authors:  Chul Hyoung Lyoo; Young Hoon Ryu; Myung Sik Lee
Journal:  J Neurol       Date:  2011-04-22       Impact factor: 4.849

2.  Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease.

Authors:  Janey Prodoehl; Mathew Spraker; Daniel Corcos; Cynthia Comella; David Vaillancourt
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

3.  Distinct spatiotemporal patterns for disease duration and stage in Parkinson's disease.

Authors:  Simon Badoud; Nicolas Nicastro; Valentina Garibotto; Pierre R Burkhard; Sven Haller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-29       Impact factor: 9.236

4.  Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease.

Authors:  Gaetano Barbagallo; Maria Eugenia Caligiuri; Gennarina Arabia; Andrea Cherubini; Angela Lupo; Rita Nisticò; Maria Salsone; Fabiana Novellino; Maurizio Morelli; Giuseppe Lucio Cascini; Domenico Galea; Aldo Quattrone
Journal:  Hum Brain Mapp       Date:  2017-06-20       Impact factor: 5.038

5.  The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.

Authors:  Orazio Schillaci; Mariangela Pierantozzi; Luca Filippi; Carlo Manni; Livia Brusa; Roberta Danieli; Giorgio Bernardi; Giovanni Simonetti; Paolo Stanzione
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-08       Impact factor: 9.236

Review 6.  Early diagnosis of Parkinson's disease.

Authors:  Jörg Spiegel; Alexander Storch; Wolfgang H Jost
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

7.  Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.

Authors:  S Happe; T Tings; W Koch; J Welsch; K Helmschmied; P C Baier; J Meller; W Wuttke; W Paulus; K Tatsch; C Trenkwalder
Journal:  J Neural Transm (Vienna)       Date:  2006-12-28       Impact factor: 3.575

8.  Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model.

Authors:  David J Brooks
Journal:  Wien Klin Wochenschr       Date:  2006-10       Impact factor: 1.704

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

10.  Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson's disease: a correlation study.

Authors:  Estelle Dellapina; Jean Pellaprat; Djilali Adel; Jerome Llido; Estelle Harroch; Jean Baptiste Martini; Aurélie Kas; Anne Sophie Salabert; Fabienne Ory-Magne; Pierre Payoux; Christine Brefel-Courbon
Journal:  J Neural Transm (Vienna)       Date:  2019-01-31       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.